Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.775p 0.75p 0.80p 0.775p 0.775p 0.775p 2,633,258 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 0.4 0.0 38.8 21.28

Sareum Share Discussion Threads

Showing 28476 to 28499 of 28500 messages
Chat Pages: 1140  1139  1138  1137  1136  1135  1134  1133  1132  1131  1130  1129  Older
DateSubjectAuthorDiscuss
19/9/2018
16:24
So Sar being mentioned with the big boys yet share price in the doldrums. This will finish the day red on a good rns day
spacedust
18/9/2018
15:53
Perhaps an RNS IS ON ITS WAY!
herb clark
18/9/2018
15:37
mrblonde77: is mrsblonde having more of an affect on you than you realise? ;-)
walter walcarpets
18/9/2018
15:36
Strange Cerrito, I had the text alert and email alert too, got me all excited over nothing... story of my life with SAR so far
mrblonde77
18/9/2018
15:15
anyone else get an RNS Alert through today about 2pm?? Looked but all i could see was one from 11September?
mrblonde77
18/9/2018
12:03
so Sareum now being mentioned alongside the big boys...
skez13
18/9/2018
11:14
Sareum Holdings plc tweet today Good summary of the clinical and preclinical TYK2 inhibitors, including the Sareum TYK2/JAK1i, SDC-1801: Tyk2 reaches tipping point hTtp://www.evaluate.com/vantage/articles/analysis/tyk2-reaches-tipping-point … $SAR.L #AIM #biotech #TYK2 #JAK1
chrisatrdg
17/9/2018
18:33
The previous chairman was Harper and he was a charlatan. I wouldn't trust him as far as I could kick him which wouldn't have been far because he was more than a little rotund....
nobbygnome
17/9/2018
17:52
Parker ,who has an impressive resume, gets £46.5k in fees as per last AR as Chairman- a high amount for a company with a marcap of £20m and well in excess of his predecessor. That said he will be worth his weight in Gold if he can successfully see through the financing challenges of the next few months either by getting a good licensing deal and/or a good equity raise bringing in institutional shareholders and getting them to accept the reality that the current share price reflects the price for £5k trades but not big amounts. In theory one option could be to get financing by assigning proceeds of next milestone but that would require divulging details of milestone agreement, to which SAR is not a party, and no idea if that is a goer. Ps Thanks to Mrs A for updates on wider industry developments ref tyk2 PPS Concerned that I am spending too much time on this but at the same time we are in an intriguing situation.
cerrito
16/9/2018
18:20
Usually you would expect companies to want clinical data before they license such a compound. However, as you say the target has been validated so perhaps that will not be the case here.
nobbygnome
16/9/2018
16:38
We have had data from bms and pfizer this week confirming tyk2 as a class is safe and effective. And they will both progress into large p3 trials. We are the only tyk2 avaable for licence. Big derisk for any prospective licencee this week and corresponding uplift to our value. Eventually.....
mrsapeslaptop
15/9/2018
23:27
Thanks hickersp for nudging me to the SAR twitter thread and the following article hxxps://quoteddata.com/2018/09/23925/ which provides a basic summary of where we are. Good for Tim that it references Pfizer and SAR in the same breath; the key is if this can be monetized before they run out of money and only time will tell.
cerrito
15/9/2018
16:06
One or two interesting tweets from Sareum twitter in the last couple of days.......
hickersp
14/9/2018
19:36
Millions bought.
spacedust
14/9/2018
11:27
Can buy as many as you want. Millions available.
spacedust
14/9/2018
10:19
Can't buy online with HL
herb clark
13/9/2018
20:37
If so then maybe we might hit 1.2p then back down again on fantastic news
spacedust
12/9/2018
20:47
Bms releaed its tyk2 dat psoriasis today phase 2. Very safe and very effective. Proves the class of drugs and de risks for potential licencees. I expect tim doung pr inteeviews within a week referencing bms data. And a deal within a month. And my guess is gsk will win it. Poss placing aside. But bms data on the class is outstanding imho.
mrsapeslaptop
11/9/2018
18:43
Crt / icr have had an aurora sitting ready for licence for years. No takers to date. Tyk2 is the money. Imho.
mrsapeslaptop
11/9/2018
16:36
I remember last time Tim promised to sign a deal 'by the end of the year'. Despite reiterating frequently he completely failed; I bought in on the basis of his frequent assertions of success. So don't hold your breath for a Aurora deal.....
nobbygnome
11/9/2018
14:54
So we are now at a 1.5m loss!!!! Timber time
spacedust
11/9/2018
10:13
Its a bit of a guess on when the next milestone is due. My guesstimtae is c £4.5m on completion of recruitment. which on the revised plans I guesstimate Feb next year. so frankly a bit of a punt without any facts and just guesswork. For prudence I think they need to place just in case unless they have a Tyk2 partner closing. BMS data later this week and then I think we will see some PR from Tim that may give more clues.
mrsapeslaptop
11/9/2018
10:03
Given that in five weeks time approx. we are getting the Finals I was a bit surprised to get this morning’s trading update, I see they did the same last year on August 22 and I guess had to wait till they had news of SDC-1801. I read this that there has been no progress on Aurora toxicity and note they have not given a timeline for TYK cancer candidate selection. All SRA737 comments already in the public domain. The cash balance was very slightly better than what I had anticipated. Given that a lot of this cash is going on R&D there will be an increase in the tax credits. They had tax receivable of £150k at 12.17 but not see these funds as being sufficiently big and indeed disbursed quick enough to defer the placing till next year.
cerrito
10/9/2018
23:42
Following what I thought was a good news story this morning, I did think about buying more but was put off by question marks as to how this will be funded and the need for an equity raise- no doubt the reason for the fall this afternoon. I note no mention-even in passing- of T-ALL. I guess we need to wait till the Finals come out. I also wonder where SRI stand in this. Over the years they have done the biology on the auto immune programmes and SAR the chemistry. No idea if this division of labour will continue in the future. Indeed I need to say I am unsure if chemistry more important/ expensive than biology. In the past there have been delays as SRI has had to get US Government funding and no idea if that is the case here. I went to the SRI website and typed in TYK2 autoimmune diseases and there were three items on the SRI/SAR partnership from 2013/4 but nothing since then. These are questions for the AGM. Ps Congratulations to Mrs.A for forecasting this.
cerrito
Chat Pages: 1140  1139  1138  1137  1136  1135  1134  1133  1132  1131  1130  1129  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180924 19:44:03